未登录 分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study 真实世界生存结局、治疗模式及PD-L1表达对加拿大接受CRT→度伐利尤单抗治疗的不可切除、Ⅲ期NSCLC患者的影响：RELEVANCE研究 Wheatley-Price, Paul; Navani, Vishal; Pabani, Aliyah; Routy, Bertrand; Snow, Stephanie; Denault, Marie-Helene; Kim, YongJin; Syed, Iqra; Devost, Natalie; Hui, Daphne; Qadeer, Rana A.; Arora, Paul; Velummailum, Russanthy; Springford, Aaron; McKibbon, Chelsea; Ho, Cheryl 分享 收藏
The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer 癌基因驱动的晚期非小细胞肺癌新疗法的不断发展 Melosky, Barbara; Juergens, Rosalyn A.; Banerji, Shantanu; Sacher, Adrian; Wheatley-Price, Paul; Snow, Stephanie; Tsao, Ming-Sound; Leighl, Natasha B.; Martins, Ilidio; Cheema, Parneet; Liu, Geoffrey; Chu, Quincy S. C. 分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
A genomic scar based signature (HRDsig) and biallelic BRCA alterations identify a homologous recombination deficiency (HRD) phenotype of non-small cell lung cancer (NSCLC) potentially actionable to the PARP inhibitor rucaparib: Post-hoc analysis of lung-MAP substudy S1900A 基于基因组疤痕特征的签名（HRDsig）和双等位基因BRCA突变可识别非小细胞肺癌（NSCLC）的同源重组缺陷（HRD）表型，该表型可能对PARP抑制剂rucaparib具有潜在可操作性：肺-MAP亚研究S1900A的事后分析 Riess, J. W.; Miao, J.; Wheatley-Price, P.; Reckamp, K. L.; Kozono, D.; Redman, M. W.; Edelman, M. J.; Faller, B.; Villaruz, L.; Corum, L.; Gowda, A.; Srkalovic, G.; Osarogiagbon, R.; Baumgart, M.; Gandara, D. R.; Sokol, E. S.; Borghaei, H.; Gray, J. E.; Herbst, R. S.; Kelly, K. 分享 收藏
分享 收藏
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial 生物标志物定向靶向治疗联合durvalumab治疗晚期非小细胞肺癌: 2期伞形试验 Besse, Benjamin; Pons-Tostivint, Elvire; Park, Keunchil; Hartl, Sylvia; Forde, Patrick M.; Hochmair, Maximilian J.; Awad, Mark M.; Thomas, Michael; Goss, Glenwood; Wheatley-Price, Paul; Shepherd, Frances A.; Florescu, Marie; Cheema, Parneet; Chu, Quincy S. C.; Kim, Sang-We; Morgensztern, Daniel; Johnson, Melissa L.; Cousin, Sophie; Kim, Dong-Wan; Moskovitz, Mor T.; Vicente, David; Aronson, Boaz; Hobson, Rosalind; Ambrose, Helen J.; Khosla, Sajan; Reddy, Avinash; Russell, Deanna L.; Keddar, Mohamed Reda; Conway, James P.; Barrett, J. Carl; Dean, Emma; Kumar, Rakesh; Dressman, Marlene; Jewsbury, Philip J.; Iyer, Sonia; Barry, Simon T.; Cosaert, Jan; Heymach, John V. 分享 收藏
分享 收藏
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results Anagnostou, Valsamo; Ho, Cheryl; Nicholas, Garth; Juergens, Rosalyn Anne; Sacher, Adrian; Fung, Andrea S.; Wheatley-Price, Paul; Laurie, Scott A.; Levy, Benjamin; Brahmer, Julie R.; Balan, Archana; Niknafs, Noushin; Avrutin, Egor; Zhu, Liting; Sausen, Mark; Bradbury, Penelope A.; O'Donnell-Tormey, Jill; Gaudreau, Pierre Olivier; Ding, Keyue; Dancey, Janet 分享 收藏
分享 收藏
A ctDNA-directed, multi-center phase II study of molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer: Analysis of Stage 1 of CCTG BR.36 Anagnostou, Valsamo K.; Ho, Cheryl; Nicholas, Garth; Juergens, Rosalyn Anne; Sacher, Adrian; Fung, Andrea; Wheatley-Price, Paul; Laurie, Scott; Levy, Benjamin; Brahmer, Julie; Balan, Archana; Niknafs, Noushin; Avrutin, Egor; Zhu, Liting; Sausen, Mark; Bradbury, Penelope; O'Donnell-Tormey, Jill; Gaudreau, Pierre-Olivier; Ding, Keyue; Dancey, Janet 分享 收藏
The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer Ezeife, Doreen A.; Spackman, Eldon; Juergens, Rosalyn A.; Laskin, Janessa J.; Agulnik, Jason S.; Hao, Desiree; Laurie, Scott A.; Law, Jennifer H.; Le, Lisa W.; Kiedrowski, Lesli A.; Melosky, Barbara; Shepherd, Frances A.; Cohen, Victor; Wheatley-Price, Paul; Vandermeer, Rachel; Li, Janice J.; Fernandes, Roxanne; Shokoohi, Aria; Lanman, Richard B.; Leighl, Natasha B. 分享 收藏
.png){kind=icon}
.png){kind=icon}
.png)
ANNALS OF ONCOLOGY.png)
.png){kind=icon}
分享.png){kind=icon}
收藏